Article
Medicine, General & Internal
Massimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, Daniela Cilloni, Monica Messina, Stefano Soddu, Fausto Castagnetti, Fabio Stagno, Paola Fazi, Alessandra Iurlo, Giovanni Caocci, Antonella Gozzini, Tamara Intermesoli, Mariella DAdda, Fabrizio Pane
Summary: Unmet needs exist in later lines of chronic myeloid leukemia (CML) treatment due to poor response and overall survival in resistant patients who switch to a second-generation TKI with similar action in the second line, as well as the increase in off-target toxicities and potential mutations. However, the recent approval of asciminib, a STAMP inhibitor, in the third line could change the treatment algorithm for this patient subset. A GIMEMA survey in Italy evaluated the current number of patients receiving third-line treatment, the current approach in later lines by Italian physicians, and the perceptions about the future role of asciminib.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Orthopedics
Deepa Jeevanantham, Venkadesan Rajendran, Zachary McGillis, Line Tremblay, Celine Lariviere, Andrew Knight
Summary: This guideline provides recommendations for physical therapists managing multiple myeloma patients based on physiological markers, complete patient presentation, and the stage of medical treatment. Developed through a systematic review and consensus process, these guidelines aim to optimize rehabilitation outcomes by filling an important knowledge gap in the field.
Article
Oncology
Anna C. Pavlick, Charlotte E. Ariyan, Elizabeth Buchbinder, Diwakar Davar, Geoffrey T. Gibney, Omid Hamid, Tina J. Hieken, Benjamin Izar, Douglas B. Johnson, Rajan P. Kulkarni, Jason J. Luke, Tara C. Mitchell, Meghan J. Mooradian, Krista M. Rubin, April K. S. Salama, Keisuke Shirai, Janis M. Taube, Hussein A. Tawbi, J. Keith Tolley, Caressa Valdueza, Sarah A. Weiss, Michael K. Wong, Ryan J. Sullivan
Summary: Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has greatly transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with the possibility of cure for some patients. However, traditional immunotherapy biomarkers have failed to predict response reliably and ICIs are associated with unique toxicity profiles. The clinical practice guideline on immunotherapy aims to provide guidance for healthcare professionals and improve patient care.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Laura B. Oswald, Kelly A. Hyland, Sarah L. Eisel, Aasha Hoogland, Hans Knoop, Ashley M. Nelson, Javier Pinilla-Ibarz, Kendra Sweet, Paul B. Jacobsen, Heather S. L. Jim
Summary: TKIs significantly improve survival for CML patients, but fatigue related to TKIs can impact patients' quality of life. This study aimed to identify correlates of fatigue among CML patients taking TKIs, finding associations with BMI, sleep disturbance, and physical activity. These results could help identify patients at risk for severe fatigue during TKI therapy.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Medicine, General & Internal
Mia Bierbaum, Frances Rapport, Gaston Arnolda, Yvonne Tran, Brona Nic Giolla Easpaig, Kristiana Ludlow, Jeffrey Braithwaite
Summary: This paper presents a protocol for a systematic review aiming to determine cancer treatment CPG adherence rates in Australia across various common cancers and to identify factors associated with adherence.
Article
Medicine, General & Internal
Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fuerstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindstrom, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Bjoern Schoettker, Thomas Noesslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jaeger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brueggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek
Summary: In fit patients with CLL, venetoclax-obinutuzumab, with or without ibrutinib, showed superior results compared to chemoimmunotherapy as a first-line treatment, with higher rates of undetectable minimal residual disease and progression-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Physiology
Marco Santoro, Salvatrice Mancuso, Vincenzo Accurso, Daniela Di Lisi, Giuseppina Novo, Sergio Siragusa
Summary: Optimizing cardiovascular risk management in CML patients before and during TKI treatment involves appropriate baseline evaluation, accurate choice of therapy, improvement of modifiable risk factors, and close monitoring and prevention of cardiovascular toxicity. Preventive strategies are aimed at minimizing cardiovascular risk when CML is diagnosed, with a personalized and multidisciplinary approach to optimize treatment while managing cardiovascular risk.
FRONTIERS IN PHYSIOLOGY
(2021)
Article
Immunology
Fang Cheng, Zheng Cui, Qiang Li, Liu Wang, Weiming Li
Summary: To ensure optimal care for patients with CML, adherence to TKIs has emerged as a critical component. The study found that high adherence to TKIs treatment confers clinical benefits to patients with CML.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Hematology
Jorge Cortes, Jane Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Kevin Arthur, Lori Maness, Moshe Talpaz, Michael Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger
Summary: The study focused on the treatment of CP-CML patients with different doses of ponatinib, finding that the optimal benefit/risk outcomes were achieved with a starting dose of 45 mg and decreased to 15 mg upon response.
Article
Biochemistry & Molecular Biology
Rachid Lahlil, Anne Aries, Maurice Scrofani, Celine Zanetti, Desline Hennequin, Bernard Drenou
Summary: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by the presence of the BCR-ABL fusion gene. Treatment with tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM) has significantly improved clinical outcomes for CML patients, but IM resistance remains a major challenge. The cause of IM resistance in CML cells is unclear, but additional genetic alterations in leukemic stem cells (LSCs) are a common cause of relapse. A study found that a rare subpopulation of stem cells called very small embryonic-like stem cells (VSELs) in adult CML patients is resistant to IM and less sensitive to apoptosis compared to leukemic hematopoietic stem cells (HSCs). The expression levels of certain miRNAs are also affected in these IM-resistant VSELs, including miR-126 and miR-21, which are involved in LSC leukemia-initiating capacity and growth.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Jorge Cortes, Carolina Pavlovsky, Susanne Saussele
Summary: Tyrosine-kinase inhibitors have significantly altered the natural course of chronic myeloid leukaemia, allowing some patients to approach a near-normal life expectancy. Successful treatment requires understanding the patient's treatment goals, monitoring optimal response hallmarks, timely interventions, recognition of adverse events, and management of comorbidities.
Review
Pharmacology & Pharmacy
Gianmarco Marciano, Cristina Vocca, Maurizio Evangelista, Caterina Palleria, Lucia Muraca, Cecilia Galati, Francesco Monea, Liberata Sportiello, Giovambattista De Sarro, Annalisa Capuano, Luca Gallelli
Summary: According to the International Association for the Study of Pain, chronic pain refers to an unpleasant sensory and emotional experience linked with actual or potential tissue damage. There are different types of pain, including nociceptive, neuropathic, and nociplastic pain. This narrative review examines the characteristics of drugs used for each type of pain, following guidelines, and their effects on individuals with comorbidities to minimize severe adverse events.
Article
Cell Biology
Mohammad Houshmand, Nicoletta Vitale, Francesca Orso, Alessandro Cignetti, Ivan Molineris, Valentina Gaidano, Stefano Sainas, Marta Giorgis, Donatella Boschi, Carmen Fava, Alice Passoni, Marta Gai, Massimo Geuna, Federica Sora, Alessandra Iurlo, Elisabetta Abruzzese, Massimo Breccia, Olga Mulas, Giovanni Caocci, Fausto Castagnetti, Daniela Taverna, Salvatore Oliviero, Fabrizio Pane, Marco Lucio Lolli, Paola Circosta, Giuseppe Saglio
Summary: The study shows that the newly developed DHODH inhibitor, Meds433, is highly effective in targeting CML cells by activating the apoptotic pathway and inducing metabolic stress. This finding suggests that DHODH inhibition is a promising approach for targeting CML stem/progenitor cells.
CELL DEATH & DISEASE
(2022)
Article
Surgery
Ursula Thiem, Veronika Buxhofer-Ausch, Wolfgang Kranewitter, Gerald Webersinke, Wolfgang Enkner, Daniel Cejka
Summary: Patients with CML treated with imatinib leading to deep molecular remission may not be considered an absolute contraindication to kidney transplantation.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Oncology
Fadi G. Haddad, Hagop M. Kantarjian, Aram Bidikian, Elias J. Jabbour, Nicholas J. Short, Jing Ning, Lianchun Xiao, Naveen Pemmaraju, Courtney D. DiNardo, Tapan M. Kadia, Kayleigh R. Marx, Guillermo Garcia-Manero, Farhad Ravandi, Koji Sasaki, Ghayas C. Issa
Summary: Bariatric surgery has a negative impact on the treatment outcomes of patients with chronic myeloid leukemia, leading to lower early molecular response rates, longer time to achieve complete cytogenetic or major molecular responses, and lower survival rates.
Article
Hematology
Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Mueller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian
Article
Hematology
Tycel J. Phillips, Andres Forero-Torres, Taimur Sher, Catherine S. Diefenbach, Patrick Johnston, Moshe Talpaz, Jennifer Pulini, Li Zhou, Peggy Scherle, Xuejun Chen, Paul M. Barr
Review
Oncology
Moshe Talpaz, Giuseppe Saglio, Ehab Atallah, Philippe Rousselot
Article
Oncology
Kamal Menghrajani, Philip S. Boonstra, Jessica A. Mercer, Cecelia Perkins, Krisstina L. Gowin, Alissa A. Weber, Ruben Mesa, Jason R. Gotlib, Lixia Wang, Jack W. Singer, Moshe Talpaz
LEUKEMIA & LYMPHOMA
(2019)
Article
Biochemistry & Molecular Biology
Karen McLean, Lijun Tan, Danielle E. Bolland, Lan G. Coffman, Luke F. Peterson, Moshe Talpaz, Nouri Neamati, Ronald J. Buckanovich
Article
Oncology
Kristen Pettit, Srdan Verstovsek, Moshe Talpaz
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2019)
Article
Oncology
Marc S. Raab, Sheeba K. Thomas, Enrique M. Ocio, Andreas Guenther, Yeow-Tee Goh, Moshe Talpaz, Nicolas Hohmann, Sylvia Zhao, Fang Xiang, Carl Simon, K. Gary Vanasse, Shaji K. Kumar
Article
Oncology
Aaron T. Gerds, Tetsuzo Tauchi, Ellen Ritchie, Michael Deininger, Catriona Jamieson, Ruben Mesa, Mark Heaney, Norio Komatsu, Hironobu Minami, Yun Su, Naveed Shaik, Xiaoxi Zhang, Christine DiRienzo, Mirjana Zeremski, Geoffrey Chan, Moshe Talpaz
Correction
Oncology
Aaron T. Gerds, Tetsuzo Tauchi, Ellen Ritchie, Michael Deininger, Catriona Jamieson, Ruben Mesa, Mark Heaney, Norio Komatsu, Hironobu Minami, Yun Su, Naveed Shaik, Xiaoxi Zhang, Christine DiRienzo, Mirjana Zeremski, Geoffrey Chan, Moshe Talpaz
Article
Oncology
Gerald Falchook, Seth Rosen, Patricia LoRusso, Justin Watts, Shilpa Gupta, Catherine C. Coombs, Moshe Talpaz, Razelle Kurzrock, Monica Mita, Ryan Cassaday, Wael Harb, Julio Peguero, David C. Smith, Sarina A. Piha-Paul, Russ Szmulewitz, Marcus S. Noel, Swamy Yeleswaram, Phillip Liu, Julie Switzky, Gongfu Zhou, Fred Zheng, Amitkumar Mehta
CLINICAL CANCER RESEARCH
(2020)
Article
Hematology
Asra Ahmed, Samuel A. Merrill, Fares Alsawah, Paula Bockenstedt, Erica Campagnaro, Sumana Devata, Scott D. Gitlin, Mark Kaminski, Alice Cusick, Tycel Phillips, Suman Sood, Moshe Talpaz, Albert Quiery, Philip S. Boonstra, Ryan A. Wilcox
LANCET HAEMATOLOGY
(2019)
Article
Hematology
Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Eric Jourdan, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Juan Shen, Tymara Berry, Carrie Brownstein, Ruben A. Mesa
AMERICAN JOURNAL OF HEMATOLOGY
(2020)
Article
Medicine, General & Internal
T. P. Hughes, M. J. Mauro, J. E. Cortes, H. Minami, D. Rea, D. J. DeAngelo, M. Breccia, Y. -T. Goh, M. Talpaz, A. Hochhaus, P. le Coutre, O. Ottmann, M. C. Heinrich, J. L. Steegmann, M. W. N. Deininger, J. J. W. M. Janssen, F. -X. Mahon, Y. Minami, D. Yeung, D. M. Ross, M. S. Tallman, J. H. Park, B. J. Druker, D. Hynds, Y. Duan, C. Meille, F. Hourcade-Potelleret, K. G. Vanasse, F. Lang, D. -W. Kim
NEW ENGLAND JOURNAL OF MEDICINE
(2019)
Review
Hematology
Benjamin Garmezy, Jordan K. Schaefer, Jessica Mercer, Moshe Talpaz
Summary: Treatment options for primary myelofibrosis are limited, but diagnosis can often be established through appropriate clinical history, examination, laboratory evaluation, and bone marrow biopsy. Recent studies have characterized prognostic factors and driver mutations better, leading to the development of treatment strategies based on risk factors and clinical phenotype.